SOX13 is a novel prognostic biomarker and associates with immune infiltration in breast cancer

Ting Gao ^1,2, Baohong Jiang ¹, Yu Zhou ¹

⁰The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.

Frontiers in Immunology +

|

May 6, 2024

View abstract on PubMed

Summary

High SOX13 expression in breast cancer (BC) correlates with poor survival and drug resistance. This study suggests SOX13 may serve as a biomarker for predicting BC prognosis and immune cell infiltration.

Area Of Science

Oncology
Molecular Biology
Cancer Genomics

Background

SOX13, a member of the SOX family of transcription factors, is implicated in various cancers.
The specific role and clinical significance of SOX13 in human breast cancer (BC) are not well understood.

Purpose Of The Study

To investigate the prognostic value and biological implications of SOX13 in breast cancer.
To explore the association of SOX13 with tumor microenvironment and drug resistance in BC.

Main Methods

Utilized public databases (UNLCAL, GEPIA, TIMER, Kaplan-Meier plotter, cBioportal, TCGA, LinkedOmics, ImmuCellAI, TIMER2.0, GDSC2) for expression, survival, mutation, copy number alteration, methylation, co-expression, immune infiltration, and drug resistance analysis.
Validated clinical specimens using immunohistochemistry (IHC).

Main Results

SOX13 expression was significantly higher in BC tissues compared to normal tissues.
Increased SOX13 gene mutation, amplification, and expression levels were observed in BC, correlating with worse overall survival (OS).
SOX13 expression was linked to the tumor microenvironment, immune cell infiltration, and predicted resistance to a wide range of drugs.

Conclusions

High SOX13 expression is associated with poor prognosis in breast cancer.
SOX13 plays a significant role in cancer immunity and may serve as a predictive biomarker for BC prognosis and immune cell infiltration.

Keywords:

SOX13 bioinformatics analysis breast cancer immunohistochemistry prognosis